Adar1 Capital Management, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Adar1 Capital Management, LLC disclosed 267 US equity positions worth $2.1bn in its Q2 2026 13F filing. The largest position was ABVX at 11.3% of the reported book, followed by PTGX and ROIV. Against the Q1 2026 filing, it opened 2 new positions, added to 27 and reduced 18 among the top 50 holdings.
What did Adar1 Capital Management, LLC own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | Healthcare | 11.3% | $240.5m | 1,804,703 | 29% | added |
| 2 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 5.5% | $117.8m | 960,863 | -3% | reduced |
| 3 | ROIV ROIVANT SCIENCES LTD | Healthcare | 5.3% | $111.7m | 3,157,008 | -4% | reduced |
| 4 | SPY STATE STR SPDR S&P 500 ETF T | 4.5% | $96.4m | 129,087 | 70% | added | |
| 5 | IMVT IMMUNOVANT INC | Healthcare | 4.2% | $89.8m | 2,330,716 | -13% | reduced |
| 6 | ZLAB ZAI LAB LTD | Healthcare | 3.0% | $64.0m | 3,369,034 | 136% | added |
| 7 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.2% | $47.8m | 1,288,053 | 816% | added |
| 8 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 2.1% | $45.7m | 1,222,080 | 7% | added | |
| 9 | BOXX EA SERIES TRUST | 1.9% | $39.5m | 337,125 | 0% | held | |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 1.8% | $39.0m | 457,907 | -28% | reduced |
| 11 | SEPN SEPTERNA INC | Healthcare | 1.5% | $31.5m | 940,747 | -14% | reduced |
| 12 | AVR ANTERIS TECHNOLOGIES GLOBAL | 1.5% | $31.0m | 3,145,096 | -17% | reduced | |
| 13 | EDIT EDITAS MEDICINE INC | Healthcare | 1.4% | $28.8m | 8,889,000 | – | new |
| 14 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.2% | $26.5m | 1,029,080 | -45% | reduced |
| 15 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.2% | $25.2m | 283,982 | -16% | reduced |
| 16 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.2% | $25.0m | 2,456,677 | -10% | reduced |
| 17 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.2% | $24.9m | 74,253 | 4850% | added |
| 18 | INSM INSMED INC | Healthcare | 1.1% | $24.4m | 228,520 | 546% | added |
| 19 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.1% | $23.1m | 619,542 | 45% | added |
| 20 | VKTX VIKING THERAPEUTICS INC | Healthcare | 1.1% | $22.4m | 574,038 | 152% | added |
| 21 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.0% | $20.7m | 3,040,466 | 2% | added |
| 22 | MNPR MONOPAR THERAPEUTICS INC | 0.9% | $20.1m | 217,595 | -18% | reduced | |
| 23 | OVID OVID THERAPEUTICS INC | Healthcare | 0.9% | $20.0m | 7,417,479 | 63% | added |
| 24 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.9% | $19.7m | 387,718 | 18% | added |
| 25 | ENTA ENANTA PHARMACEUTICALS INC | Healthcare | 0.9% | $19.6m | 1,344,510 | 2518% | added |
| 26 | NKTR NEKTAR THERAPEUTICS | Healthcare | 0.8% | $17.0m | 244,184 | 51% | added |
| 27 | INSP INSPIRE MED SYS INC | Healthcare | 0.8% | $16.7m | 374,617 | -8% | reduced |
| 28 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.8% | $16.4m | 87,509 | -35% | reduced |
| 29 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 0.7% | $15.9m | 185,619 | -13% | reduced |
| 30 | PRTA PROTHENA CORP PLC | Healthcare | 0.7% | $15.2m | 1,554,535 | -2% | reduced |
| 31 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 0.7% | $15.1m | 136,158 | -36% | reduced |
| 32 | IKT INHIBIKASE THERAPEUTICS INC | 0.7% | $15.0m | 7,387,205 | 12% | added | |
| 33 | UNIQURE NV | 0.7% | $15.0m | 324,672 | 326% | added | |
| 34 | RLYB RALLYBIO CORP | 0.7% | $14.8m | 926,352 | 4411% | added | |
| 35 | REGN REGENERON PHARMACEUTICALS | Healthcare | 0.7% | $13.8m | 22,208 | 83% | added |
| 36 | IVA INVENTIVA SA | 0.6% | $13.6m | 3,606,656 | 66% | added | |
| 37 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.6% | $13.4m | 404,014 | -23% | reduced |
| 38 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 0.6% | $13.2m | 166,286 | 4% | added |
| 39 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.6% | $13.2m | 176,689 | 87% | added |
| 40 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 0.6% | $13.1m | 730,649 | 179% | added |
| 41 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 0.6% | $12.6m | 3,365,118 | -1% | reduced |
| 42 | VOR VOR BIOPHARMA INC | Healthcare | 0.6% | $12.5m | 680,626 | – | new |
| 43 | BIL SPDR SERIES TRUST | 0.6% | $12.4m | 135,585 | 0% | held | |
| 44 | EQ EQUILLIUM INC | 0.6% | $12.0m | 3,758,569 | 1% | added | |
| 45 | ANL ADLAI NORTYE LTD | 0.6% | $11.7m | 1,017,805 | 763% | added | |
| 46 | CLYM CLIMB BIO INC | Healthcare | 0.5% | $10.7m | 822,649 | 38% | added |
| 47 | HELIX ACQUISITION CORP III | 0.5% | $10.6m | 1,000,000 | 0% | held | |
| 48 | ZURA ZURA BIO LTD | Healthcare | 0.5% | $10.4m | 1,759,295 | 179% | added |
| 49 | OKUR ONKURE THERAPEUTICS INC | 0.5% | $10.2m | 2,238,684 | -8% | reduced | |
| 50 | MAZE MAZE THERAPEUTICS INC | Healthcare | 0.5% | $10.1m | 339,276 | 577% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.